The Legal Cannabis Market Growth in North America

Wednesday, April 5, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 5, 2017 /PRNewswire/ -- News Commentary 

The legal cannabis market

is growing rapidly in the North America. According to Arcview Market Research, people in the United States and Canada spent an estimated $53.3
on legal cannabis products in 2016. The report shows that the illegal cannabis market accounted for about 87 percent of the total sales in 2016, down from 90 percent in 2015. The black market is losing ground to the legal market as more states in the U.S. voted in favor of reforms and legalizing cannabis. Policy makers in Canada are expected to begin the process of cannabis legalization in the near future. Inc. (OTC: CIIX), OWC Pharmaceutical Research Corporation (OTC: OWCP), General Cannabis Corporation (OTC: CANN), United Cannabis Corporation (OTC: CNAB), Corbus Pharmaceuticals (NASDAQ: CRBP).

According to reports from Canadian national broadcaster, CBC News, the current Liberal government in Canada will announce legislation this month to legalize cannabis in Canada by July 1, 2018. The new law will allow adults with a minimum age of 18 to purchase cannabis and grow up to four cannabis plants per household. The report also said that the federal government will be in charge of licensing producers, while provincial governments will have the right to set price and manage distribution. Inc. (OTCQB: CIIX) earlier today announced, "It will attend the 'Invest 2017' exhibition in Stuttgart, Germany which will take place from April 7th-8th, 2017. Invest 2017 is the leading trade fair and congress for finance and investment in Germany and provides CIIX the opportunity to introduce its media and nutritional hemp companies, and to German investors.

Invest 2017 is considered to be the No. 1 meeting point for the finance and investment sector in Germany. As one of the largest financial sector events in Germany, it attracted more than 12,000 visitors and 144 exhibitors in 2016. Many private and institutional investors use the platform to obtain information, compare assets and invest while exhibitors have the opportunity to generate interest in raising investment capital for their ventures."

"I am delighted that CIIX is invited to attend 'Invest 2017' as an exhibitor. This exhibition provides CIIX a valuable opportunity to introduce our nutritional hemp business to the German financial sector and meet numerous potential investors," says Warren Wang, Founder and CEO of CIIX. He further added, "In March 2017, an act to legalize the use of cannabis for medicinal purposes was passed by the German parliament. The recent approval of medical cannabis will be good for the development of the hemp-based CBD market in Germany."

OWC Pharmaceutical Research Corporation (OTCQB: OWCP) is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments that target a variety of diseases and medical indications. The company works to bring patients better outcomes by identifying unique formulation and efficient delivery systems. The company offers Sublingual Soluble Tablets and Topical Creams. Its Tablets provide patients with an adequate alternative to smoking cannabis buds for the treatment and management of pain, and its Topical Cream treats various skin diseases, such as Psoriasis.

General Cannabis Corporation (OTCQB: CANN) is the all-in-one resource for the highest quality service providers available to the regulated cannabis industry. General Cannabis is a trusted partner to the cultivation, production and retail sides of the cannabis business through a combination of strong operating divisions such as security, marketing, operational consulting and products, real estate and financing. As a synergistic holding company, its divisions are able to leverage the strengths of each other, as well as a larger balance sheet, to succeed. Its subsidiaries include, Chiefton Design, GC Capital, Next Big Crop, Iron Protection Group, and Chiefton Supply Company.

United Cannabis Corporation (OTCQB: CNAB) provides consulting services, proprietary products and licenses its intellectual property to businesses in the cannabis industry. United Cannabis own distinct intellectual property relating to the legalized growth, production, manufacture, marketing, management, utilization and distribution of medical and recreational marijuana and marijuana infused products. The Company's A.C.T. Now Program and patent-pending Prana Bio Nutrient Medicinals provide a comprehensive solution designed to enable physicians and patients to implement and monitor effective therapy protocols. Prana Bio Nutrient Medicinals is a comprehensive full spectrum cannabinoid system that utilizes the entire cannabis plant by controlling specific cannabinoid ratios, accurate dosing, and multiple non-abrasive delivery methods.

Corbus Pharmaceuticals (NASDAQ: CRBP) is a clinical stage biopharmaceutical company focusing on rare, life-threatening, chronic inflammatory diseases. The company's pipeline drug, Anabasum (JBT-101 or Resunab), is a first in class, synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Anabasum has the potential to be a safe and potent anti-inflammatory drug with a unique mechanism of action to treat a range of chronic inflammatory diseases. Anabasum is currently being evaluated for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ('systemic sclerosis'), dermatomyositis and systemic lupus erythematosus, four indications in which inflammation contribute to disease progression.

Please Sign Up Now at to receive alerts on trending financial news from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, expects to be compensated three thousand dollars for financial news dissemination and PR services by Inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a two year agreement with inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition., by accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: +1-877-601-1879 Url:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store